FORM 3

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

## INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL						
OMB Number:	3235-0104					
Estimated average burden						
hours per response:	0.5					

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  Twiford J Rainer  2. Date of Event Requiring Stateme (Month/Day/Year) 01/29/2015			3. Issuer Name and Ticker or Trading Symbol  Tracon Pharmaceuticals, Inc. [ TCON ]					
Last) (First) (Middle) 3910 UNIVERSITY CENTER LANE			Relationship of Reporting Person(s) to Issuer (Check all applicable)     X Director 10% Owner		(Mor	5. If Amendment, Date of Original Filed (Month/Day/Year)		
SUITE 700			Officer (give title below)	Other (spec		6. Individual or Joint/Group Filing (Check Applicable Line)		
(Street) SAN DIEGO CA 92122			X			Form filed by One Reporting Person  Form filed by More than One Reporting Person		
(City) (State) (Zip)								
٦	Γable I - Noι	n-Derivat	tive Securities Beneficiall	y Owned				
1. Title of Security (Instr. 4)			2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownershi Form: Direct or Indirect ( (Instr. 5)	t (D)   (Instr	4. Nature of Indirect Beneficial Ownership (Instr. 5)		
Common Stock			10,029	I	By M	By MCT Investments, LLC <sup>(1)</sup>		
Common Stock			437,210	I		By Brookline Tracon Investment Fund, LLC <sup>(2)</sup>		
Common Stock		49,380	I	I By CSA Biotechnol		ology Fund I, LLC <sup>(2)</sup>		
Common Stock		93,460	I	I By CSA Biotechnology Fund		ology Fund II, LLC <sup>(2)</sup>		
(e.			e Securities Beneficially ants, options, convertible		5)			
1. Title of Derivative Security (Instr. 4) 2. Da Expir (Mon			3. Title and Amount of Securit Underlying Derivative Securit		4. Conversion or Exercise	5. Ownership Form:	6. Nature of Indirect Beneficial Ownership (Instr. 5)	
	Date Exercisable	Expiratior Date	n Title	Amount or Number of Shares	Price of Derivative Security	Direct (D) or Indirect (I) (Instr. 5)		
Series A Redeemable Convertible Preferred Stock	(3)	(3)	Common Stock	416,059	(4)	I	By Brookline Tracon Investment Fund II, LLC <sup>(2)</sup>	
Series B Redeemable Convertible Preferred Stock	(3)	(3)	Common Stock	241,493	(4)	I	By Brookline Tracon Investment Fund II. LLC	

## **Explanation of Responses:**

- $1. \ The \ Reporting \ Person's \ spouse \ has \ voting \ and \ investment \ power \ with \ respect \ to \ the \ shares \ held \ by \ MCT \ Investments, \ LLC.$
- 2. The Reporting Person has voting and dispositive control over these shares and disclaims beneficial ownership except to the extent of his pecuniary interest therein.
- 3. The shares are convertible at any time at the holder's election, and automatically upon the closing of the Issuer's initial public offering, and have no expiration date.
- 4. The preferred stock is convertible into the number of shares of the Issuer's common stock shown in Column 3 above at a rate of 1 share of common stock for each 3.87 shares of preferred stock.

## Remarks:

/s/ Patricia L. Bitar, Attorneyin-Fact

01/29/2015

\*\* Signature of Reporting Person

Date

 $Reminder: \ Report \ on \ a \ separate \ line \ for \ each \ class \ of \ securities \ beneficially \ owned \ directly \ or \ indirectly.$ 

- $^{\ast}$  If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Know all, by these presents, that the undersigned hereby constitutes and appoints each of H Casey Logan and Patricia Bitar, signing individually, the undersigned's true and lawful attorneys-in fact and agents to:

- (1) execute for and on behalf of the undersigned, an officer, director or holder of 10% of more of a registered class of securities of TRACON Pharmaceuticals, Inc. (the "Company"), Forms 3, 4 and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended (the "Exchange Act") and the rules thereunder;
- (2) do and perform any and all acts for and on behalf of the undersigned that may be necessary or desirable to complete and execute such Form 3, 4 or 5, complete and execute any amendment or amendments thereto, and timely file such forms or amendments with the United States Securities and Exchange Commission and any stock exchange or similar authority; and
- (3) take any other action of any nature whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to

do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Exchange Act.

This Power of Attorney shall remain in full force and effect until the earliest to occur of (a) the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, (b) revocation by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact or (c) as to any attorney-in-fact individually, until such attorney-in-fact shall no longer be employed by the Company.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 27th day of January, 2015.

/s/ J. Rainer Twiford